The Czech Republic has adopted a new national strategy for rare diseases, setting priorities for coordinated, patient-centred care and stronger integration with European initiatives over the next decade.

Czech Republic adopts national strategy for rare diseases 2026–2035

Garden by Straka Academy in Malá Strana, Prague

The Czech Government has approved a new National Strategy for Rare Diseases for 2026–2035, establishing a long-term framework to improve care, diagnosis and support for people living with rare conditions. Developed by the Ministry of Health in collaboration with experts and patient organisations, the strategy aims to build a more coordinated and patient-centred system. Further information is available on the Czech Ministry of Health website.

The strategy prioritises improved coordination of care, faster and more accurate diagnosis, and expanded access to specialised services. It also places strong emphasis on the use of health data, including the development of a national rare disease registry, to support better planning and evaluation of care.

In addition, the framework promotes stronger links between healthcare and social services, aiming to ensure continuity of care throughout patients’ lives. Measures such as enhanced care coordination and improved access to information are expected to help patients and families navigate complex care pathways more effectively.

The strategy also reinforces national and international collaboration, including continued engagement with European Reference Networks (ERNs), helping to connect national expertise with wider European knowledge and resources.

News photo by Czech Wikipedia user Packa CC BY-SA 3.0

News & Updates

You might also be interested in

ERDERA’s ethics and regulatory experts are launching a dedicated webinar series to help the rare disease research community navigate two fast-moving areas of biomedical research: Advanced Therapy Medicinal Products (ATMPs) and Artificial Intelligence.
July 24 @ 3:00 pm - 4:00 pm
This webinar will present a theoretical framework for situating ethics across research activities. The framework will then be brought to life through a relevant case study discussion, giving participants a concrete reference point for the episodes ahead.
ERDERA (the European Rare Diseases Research Alliance) has opened its Clinical Trial Call to support multinational early-phase clinical trials in rare diseases. The call will fund studies designed to generate robust clinical evidence, strengthen regulatory readiness and make rare disease trials more feasible across countries.
Feedback is open until 14 July 2026, giving stakeholders an early opportunity to comment during the preparation of a likely legislative proposal for a Council regulation.